Eisai, Biogen.

On the 6th, the U.S. Food and Drug Administration (FDA) formally approved the new dementia drug "Aduhelm" developed by Eisai and Biogen. It is the first pharmaceutical to prove its effectiveness in slowing the progression of the disease. It is expected to be rapidly adopted in the future as the U.S. elderly public medical insurance "Medicare" is expected to select it for insurance coverage.